Idiopathic Pulmonary Fibrosis

Latest News in Idiopathic Pulmonary Fibrosis

July 18, 2025

Bristol-Myers Squibb’s Promising Phase 3 Study on Idiopathic Pulmonary Fibrosis Treatment – TipRanks

July 16, 2025

FDA Grants Orphan Drug Designation to Taladegib, Potential Idiopathic Pulmonary Fibrosis Treatment – HCPLive

July 16, 2025

Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis – Business Wire

July 7, 2025

Rare disease idiopathic pulmonary fibrosis rises with aging population – koreabiomed.com

July 2, 2025

Uridine alleviates the aging of alveolar epithelial cells in idiopathic pulmonary fibrosis through the Keap1-Nrf2 signaling pathway – Nature

101 Active Idiopathic Pulmonary Fibrosis Clinical Trials

As of July 12, 2025

Source: clinicaltrials.gov

LOCATE

CLINICAL TRIALS

BROWSE

FDA-approved DRUGS

WHAT IS

CONGRESS DOING?